Brefeldin A blocks the response of cultured cells to cholera toxin. Implications for intracellular trafficking in toxin action.
Cholera toxin (CT) consists of a pentameric B subunit which binds to ganglioside GM1 on the cell surface and an A subunit which activates adenylylcyclase. The latter process involves the reduction of A to the A1 peptide which ADP-ribosylates the stimulatory G protein, Gs of adenylylcyclase. There is a distinct lag phase between toxin binding and activation of adenylylcyclase. Little is known about the events during this lag including where A1 is generated and how it gains access to Gs on the cytoplasmic side of the plasma membrane. We explored the effects of several inhibitors of intracellular trafficking on the response of human SK-N-MC neurotumor and Caco-2 intestinal tumor cells to CT. Whereas chloroquine or monensin had little or no effect on CT stimulation of cyclic AMP accumulation, brefeldin A (BFA) totally inhibited the response to CT in a time- and dose-dependent and reversible manner. BFA was effective when added at the same time as CT and had an IC50 of 30 ng/ml. BFA did not alter cell surface GM1 as cells treated with BFA for 30 min bound as much 125I-CT as control cells. Furthermore, BFA inhibited CT stimulation of GM1-treated rat glioma C6 cells. BFA treatment did not affect beta-adrenergic agonist stimulation of cyclic AMP. In addition, adenylylcyclase was activated by A1 peptide and NAD+ to the same extent in membranes from control and BFA-treated cells, or when BFA was added directly to the assay. Whereas control cells generated small amounts of A1 from bound CT with time, no A1 was detected in BFA-treated cells. BFA treatment did not prevent the internalization of CT but did inhibit its degradation. BFA is known to disrupt the organization of the Golgi complex, resulting in inhibition of protein transport from the endoplasmic reticulum and redistribution of Golgi enzymes to the endoplasmic reticulum. BFA also prevents the formation of non-clathrin-coated vesicles from Golgi membranes and thus vesicular transport between Golgi cisternae. We confirmed that BFA caused the morphological disruption of the Golgi apparatus in Caco-2 cells. The data support a role for a functional Golgi apparatus with its associated vesicular routing in CT action.
Orlandi
P A
PA
Membrane Biochemistry Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Curran
P K
PK
Fishman
P H
PH
D000230:Adenocarcinoma; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D020126:Brefeldin A; D002460:Cell Line; D002738:Chloroquine / Q000494:pharmacology; D002772:Cholera Toxin / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D003110:Colonic Neoplasms; D000242:Cyclic AMP / Q000378:metabolism*; D003517:Cyclopentanes / Q000494:pharmacology*; D004789:Enzyme Activation; D005910:Glioma; D006056:Golgi Apparatus / Q000187:drug effects / Q000648:ultrastructure; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D007700:Kinetics; D008985:Monensin / Q000494:pharmacology; D009183:Mycotoxins / Q000494:pharmacology; D051381:Rats; D013997:Time Factors; D014407:Tumor Cells, Cultured
D003517:Cyclopentanes; D009183:Mycotoxins; D020126:Brefeldin A; D002738:Chloroquine; D002772:Cholera Toxin; D008985:Monensin; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D007545:Isoproterenol